Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm healthcare a/s - cholecalciferol concentrate (powder form), calcium carbonate - purutabletti - 500 mg / 10 mikrog - kalsiumin yhdistelmävalmisteet d-vitamiinin ja/tai muiden lääkeaineiden kanssa

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - rasagiline tartrate - tabletti - 1 mg - rasagiliini

Euroopan unioni - suomi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumabi - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastiset aineet - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 ja 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - methadone hydrochloride - oraaliliuos - 2 mg/ml - metadoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

vectans pharma - aciclovir - bukkaalitabletti, kiinnittyvä - 50 mg - asikloviiri

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - naloxoni hydrochloridum dihydricum - injektioneste, liuos, esitäytetty ruisku - 0.91 mg/ml - naloksoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - adrenaline tartrate - injektioneste, liuos - 0.1 mg/ml - adrenaliini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - glycopyrronium bromide - injektioneste, liuos - 200 mikrog/ml - glykopyrroniumbromidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - fentanyli citras - injektioneste, liuos - 50 mikrog/ml - fentanyyli

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - suxamethonium chloride - injektio-/infuusioneste, liuos - 50 mg/ml - suksametoni